VAXX vs. AYTU, TNXP, HUGE, COCP, NRBO, VBIV, NERV, PIRS, EDSA, and NNVC
Should you be buying Vaxxinity stock or one of its competitors? The main competitors of Vaxxinity include Aytu BioPharma (AYTU), Tonix Pharmaceuticals (TNXP), FSD Pharma (HUGE), Cocrystal Pharma (COCP), NeuroBo Pharmaceuticals (NRBO), VBI Vaccines (VBIV), Minerva Neurosciences (NERV), Pieris Pharmaceuticals (PIRS), Edesa Biotech (EDSA), and NanoViricides (NNVC). These companies are all part of the "pharmaceutical preparations" industry.
Aytu BioPharma (NASDAQ:AYTU) and Vaxxinity (NASDAQ:VAXX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, profitability, valuation, community ranking, analyst recommendations, dividends, earnings, media sentiment and risk.
Aytu BioPharma presently has a consensus price target of $5.00, indicating a potential upside of 62.87%. Vaxxinity has a consensus price target of $7.00, indicating a potential upside of 5,862.52%. Given Aytu BioPharma's higher possible upside, analysts plainly believe Vaxxinity is more favorable than Aytu BioPharma.
In the previous week, Vaxxinity had 2 more articles in the media than Aytu BioPharma. MarketBeat recorded 2 mentions for Vaxxinity and 0 mentions for Aytu BioPharma. Aytu BioPharma's average media sentiment score of 0.84 beat Vaxxinity's score of 0.00 indicating that Vaxxinity is being referred to more favorably in the news media.
33.5% of Aytu BioPharma shares are owned by institutional investors. Comparatively, 83.0% of Vaxxinity shares are owned by institutional investors. 4.3% of Aytu BioPharma shares are owned by insiders. Comparatively, 59.1% of Vaxxinity shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Aytu BioPharma has higher revenue and earnings than Vaxxinity. Aytu BioPharma is trading at a lower price-to-earnings ratio than Vaxxinity, indicating that it is currently the more affordable of the two stocks.
Vaxxinity has a net margin of 0.00% compared to Vaxxinity's net margin of -18.27%. Vaxxinity's return on equity of -41.00% beat Aytu BioPharma's return on equity.
Aytu BioPharma has a beta of -1.23, indicating that its share price is 223% less volatile than the S&P 500. Comparatively, Vaxxinity has a beta of 2.79, indicating that its share price is 179% more volatile than the S&P 500.
Aytu BioPharma received 250 more outperform votes than Vaxxinity when rated by MarketBeat users. Likewise, 67.11% of users gave Aytu BioPharma an outperform vote while only 38.46% of users gave Vaxxinity an outperform vote.
Summary
Vaxxinity beats Aytu BioPharma on 10 of the 16 factors compared between the two stocks.
Get Vaxxinity News Delivered to You Automatically
Sign up to receive the latest news and ratings for VAXX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VAXX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Vaxxinity Competitors List
Related Companies and Tools
